Highlight news

The Therapeutic Goods Administration (TGA) has provisionally approved the Pfizer vaccine as safe and effective for use for 5 to 11-year-old children in Australia. 

Subject to final considerations and recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI), and other related approvals, the Australian Government has indicated its intention to start rolling out the Pfizer vaccine to this age group from 10 January 2022. 

The Government expects to receive ATAGI’s recommendations on how to incorporate this safe and effective vaccine into Australia’s COVID-19 vaccination program within the next two weeks. 

It is anticipated the general practices which are already participating in the vaccination rollout will be given the option to order supplies of this vaccine as part of their usual ordering process.  Allocations will also be provided to states and territories for their vaccination programs. 

More information, including about the additional training which will be required to administer this vaccine, will be provided as it becomes available. 

All news

The Therapeutic Goods Administration (TGA) has provisionally approved the Pfizer vaccine as safe and effective for use for 5 to 11-year-old children in Australia. 

Subject to final considerations and recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI), and other related approvals, the Australian Government has indicated its intention to start rolling out the Pfizer vaccine to this age group from 10 January 2022. 

The Government expects to receive ATAGI’s recommendations on how to incorporate this safe and effective vaccine into Australia’s COVID-19 vaccination program within the next two weeks. 

It is anticipated the general practices which are already participating in the vaccination rollout will be given the option to order supplies of this vaccine as part of their usual ordering process.  Allocations will also be provided to states and territories for their vaccination programs. 

More information, including about the additional training which will be required to administer this vaccine, will be provided as it becomes available.